METHOD OF DETERMINING THE RISK GROUP FOR PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY PLASMACYTOMA Russian patent published in 2023 - IPC G01N33/68 G01N33/577 C12Q1/6841 

FIELD: medicine; hematology.

SUBSTANCE: invention can be used to determine the risk group for patients with multiple myeloma (MM) complicated by plasmacytoma. The plasmacytoma sample from the patient is obtained and prepared. Plasmacytoma biopsy is analyzed by immunohistochemical method to detect the expression of markers CCND1, NSD2, MAF. The patient is considered to be at high risk if NSD2 and/or MAF protein expression is detected. In the absence of the expression of three proteins or the detection of only the expression of the CCND1 protein, the patient is referred to the standard risk group.

EFFECT: method provides increased efficiency in determining the risk group in MM occurring with plasmacytoma, reducing the time for analysis, the possibility of a retrospective assessment of the risk group using a paraffin block of plasmacytoma, as well as expanding the arsenal of methods that allow determining the risk group due to immunohistochemical studies of the expression of CCND1, NSD2 markers, MAF in plasmacytoma biopsy.

2 cl, 2 dwg, 3 tbl, 5 ex